Regeneron Pharmaceuticals, Inc. (REGN)

NASDAQ: REGN · Real-Time Price · USD

819.09

+13.42 (1.67%)

At close: Oct 22, 2026, 4:00 PM EDT

818.00

-1.09 (-0.13%)

After-hours: Oct 22, 2026, 5:04 PM EDT

Regeneron Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	4,329	4,505	4,413	3,954	4,338	8,075
Depreciation & Amortization	528.6	543.7	482.9	421	341.4	286.2
Asset Writedown & Restructuring Costs	-	-	-	-	195	-
Loss (Gain) From Sale of Investments	-643.1	-946.1	-118.3	266.4	36.8	-387
Stock-Based Compensation	986.7	993.7	982.8	885	725	601.7
Other Operating Activities	-537.8	-649.9	-721.2	-837.9	-378.4	421.6
Change in Accounts Receivable	-968.8	498.1	-554	-338.8	707.8	-1,927
Change in Inventory	-82.1	-275.3	-619.7	-271.7	-696.5	-494.3
Change in Accounts Payable	1,335	736.8	735.1	598.6	-138.4	866.1
Change in Unearned Revenue	217	-51.7	227.8	37.9	32.4	-120.2
Change in Other Net Operating Assets	-482.8	-375.3	-407.5	-120.1	-148.6	-240.7
Operating Cash Flow	4,681	4,979	4,421	4,594	5,015	7,081
Operating Cash Flow Growth	-1.31%	12.63%	-3.78%	-8.39%	-29.18%	170.47%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-920.9	-898.4	-755.9	-718.6	-590.1	-551.9
Sale of Property, Plant & Equipment	-	-	20.1	-	-	-
Cash Acquisitions	-3.3	-3.3	-16.5	-54.9	-230.3	-
Sale (Purchase) of Intangibles	-185.2	-315.3	-125.7	-207.8	-1,027	-
Investment in Securities	405.2	587.9	-1,590	-2,204	-1,937	-4,833
Investing Cash Flow	-704.2	-629.1	-2,468	-3,185	-3,785	-5,385

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Issuance of Common Stock	756.1	635.9	1,465	1,146	1,520	1,672
Repurchase of Common Stock	-3,902	-3,971	-3,632	-2,936	-2,529	-2,678
Common Dividends Paid	-378.5	-370.3	-	-	-	-
Other Financing Activities	-	-10.3	-33.4	-	-	-
Financing Cash Flow	-3,525	-3,715	-2,201	-1,790	-1,009	-1,006

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	-1.9	0.3	-0.7	-0.4	-	-
Net Cash Flow	450.4	634.7	-248.8	-381.6	221.3	690.8

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	3,760	4,081	3,665	3,875	4,425	6,529
Free Cash Flow Growth	-2.42%	11.35%	-5.44%	-12.42%	-32.23%	225.90%
Free Cash Flow Margin	24.21%	28.45%	25.80%	29.54%	36.35%	40.63%
Free Cash Flow Per Share	35.13	37.57	31.84	34.08	38.98	58.19
Levered Free Cash Flow	3,065	3,258	2,636	2,763	2,628	4,309
Unlevered Free Cash Flow	3,100	3,286	2,670	2,808	2,665	4,345

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash Interest Paid	41.6	41.6	52.6	73.1	53.7	55.8
Cash Income Tax Paid	1,253	1,253	743	870.3	1,502	1,218
Change in Working Capital	18.2	532.6	-618.3	-94.1	-243.3	-1,917

SEC Filings: 10-K · 10-Q